17thApril 2017,Vadodara ,India
PRESS RELEASE
SuccessfulUS FDA I nspection at Alembi c Pharmaceuticals BioeguivalenceFacility atBaroda
Alembic PharmaceuticalsLimited today announced that the US Food&Drug Administration (US FDA)inspected itsBioequivalence facility at Baroda(Gujarat,India) between 5th& 10thMarch,2017,between 13th& 1]1hMarch,2017and between 10th&12thApril, 2017for
Bioequivalence Clinical
Bioequivalence Bioanalytical
Pharmacovigilance
All have been successfullyclearedwithout any483observations.About AlembicPharmaceut i cals Limited
Alembic Pharmaceuticals Limited, a verticallyintegrated research anddevelopment pharmaceutical company, has been at the forefront of healthcare since 1907.Headquartered in India,Alembic isapublicly listedcompany that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities ofmany developed countries including the US FDA.Alembic is one of the leaders in branded generics in India. Alembic's brands,marketed through a marketing team of over 5000arewell recognized by doctors and patients.
Information about the company can be found at www.alembic-india.com;(Reuters:ALEM .NS) (Bloomberg:ALPM) (NSE: APLLTD) (SSE:533573)
For further informationcontact:
Ajay KumarDesai Mitanshu Shah
Phone: +91 22 - 306 11681Phone: +91 265 - 3007630
Email: ajay.desai@alembic.co.in Email: mitanshu.shah@alembic.co.in
Disclaimer:
Thispress release contain statements that may constitute "forwardlooking statements"includingand without limitation,statements relating to product characteristics and uses, sales potential andtarget dates for product launch,implementation ofstrategic initiatives, and otherstatements relatingto our future business developments andeconomic performance. While these forward looking statements represent our judgmentand future expectations concerning thedevelopment of our business,a number of risks,uncertainties and other factors could cause actual developments andresults to differmaterially from our expectations. Thecompany undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liablefor any use of this information.
ALEMBIC PHARMACEUTICALS LIMITED
REGO. OFFICE : ALEMBIC ROAD, VADODARA -390 003. NDIA •TEL :+91-0265-2280550 •FAX:+91-0265-2282837
Website:www.alembio-india.com• E-mail :alemblc@alemblc.co.in
CIN:L24230GJ2010PLC061123